Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Cancer Res ; 79(10): 2494-2510, 2019 05 15.
Article in English | MEDLINE | ID: mdl-30862719

ABSTRACT

Obesity is a risk factor for postmenopausal estrogen receptor alpha (ERα)-positive (ER+) breast cancer. Molecular mechanisms underlying factors from plasma that contribute to this risk and how these mechanisms affect ERα signaling have yet to be elucidated. To identify such mechanisms, we performed whole metabolite and protein profiling in plasma samples from women at high risk for breast cancer, which led us to focus on factors that were differentially present in plasma of obese versus nonobese postmenopausal women. These studies, combined with in vitro assays, identified free fatty acids (FFA) as circulating plasma factors that correlated with increased proliferation and aggressiveness in ER+ breast cancer cells. FFAs activated both the ERα and mTOR pathways and rewired metabolism in breast cancer cells. Pathway preferential estrogen-1 (PaPE-1), which targets ERα and mTOR signaling, was able to block changes induced by FFA and was more effective in the presence of FFA. Collectively, these data suggest a role for obesity-associated gene and metabolic rewiring in providing new targetable vulnerabilities for ER+ breast cancer in postmenopausal women. Furthermore, they provide a basis for preclinical and clinical trials where the impact of agents that target ERα and mTOR signaling cross-talk would be tested to prevent ER+ breast cancers in obese postmenopausal women. SIGNIFICANCE: These findings show that obesity-associated changes in certain blood metabolites rewire metabolic programs in cancer cells, influence mammary epithelial cell tumorigenicity and aggressiveness, and increase breast cancer risk.


Subject(s)
Breast Neoplasms/metabolism , Estrogen Receptor alpha/metabolism , Fatty Acids, Nonesterified/metabolism , Obesity/metabolism , Signal Transduction , TOR Serine-Threonine Kinases/metabolism , Breast Neoplasms/blood , Breast Neoplasms/complications , CD36 Antigens/blood , Cell Line, Tumor , Chromatin/metabolism , Female , Gene Expression Regulation, Neoplastic , Humans , Obesity/blood , Obesity/complications , Phosphatidylinositol 3-Kinases/metabolism , Postmenopause
2.
Sci Signal ; 9(429): ra53, 2016 05 24.
Article in English | MEDLINE | ID: mdl-27221711

ABSTRACT

There is great medical need for estrogens with favorable pharmacological profiles that support desirable activities for menopausal women, such as metabolic and vascular protection, but that lack stimulatory activities on the breast and uterus. We report the development of structurally novel estrogens that preferentially activate a subset of estrogen receptor (ER) signaling pathways and result in favorable target tissue-selective activity. Through a process of structural alteration of estrogenic ligands that was designed to preserve their essential chemical and physical features but greatly reduced their binding affinity for ERs, we obtained "pathway preferential estrogens" (PaPEs), which interacted with ERs to activate the extranuclear-initiated signaling pathway preferentially over the nuclear-initiated pathway. PaPEs elicited a pattern of gene regulation and cellular and biological processes that did not stimulate reproductive and mammary tissues or breast cancer cells. However, in ovariectomized mice, PaPEs triggered beneficial responses both in metabolic tissues (adipose tissue and liver) that reduced body weight gain and fat accumulation and in the vasculature that accelerated repair of endothelial damage. This process of designed ligand structure alteration represents a novel approach to develop ligands that shift the balance in ER-mediated extranuclear and nuclear pathways to obtain tissue-selective, non-nuclear PaPEs, which may be beneficial for postmenopausal hormone replacement. The approach may also have broad applicability for other members of the nuclear hormone receptor superfamily.


Subject(s)
Drug Design , Estrogens/metabolism , Receptors, Estrogen/metabolism , Adipose Tissue/drug effects , Animals , Body Weight , Cell Proliferation , Chromatin/metabolism , Estrogen Receptor alpha/metabolism , Female , Gene Expression Regulation , Humans , Ligands , Liver/drug effects , MAP Kinase Signaling System , MCF-7 Cells , Mammary Glands, Animal/drug effects , Mice , Mice, Inbred C57BL , Mice, Knockout , Protein Binding , Protein Conformation , Signal Transduction , Uterus/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...